467 related articles for article (PubMed ID: 11448903)
1. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
3. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
Grem JL; Sorensen JM; Cullen E; Takimoto CH; Steinberg SM; Chen AP; Hamilton JM; Arbuck SG; McAtee N; Lawrence D; Goldspiel B; Johnston PG; Allegra CJ
Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid.
Smith GK; Amyx H; Boytos CM; Duch DS; Ferone R; Wilson HR
Cancer Res; 1995 Dec; 55(24):6117-25. PubMed ID: 8521402
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
7. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
Beutel G; Glen H; Schöffski P; Chick J; Gill S; Cassidy J; Twelves C
Clin Cancer Res; 2005 Aug; 11(15):5487-95. PubMed ID: 16061865
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.
Plummer R; Rees C; Hughes A; Beale P; Highley M; Trigo J; Gokul S; Judson I; Calvert H; Jackman A; Mitchell F; Smith R; Douglass E
Clin Cancer Res; 2003 Apr; 9(4):1313-22. PubMed ID: 12684399
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Lyass O; Hubert A; Gabizon AA
Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.
Rees C; Beale P; Trigo JM; Mitchell F; Jackman A; Smith R; Douglass E; Judson I
Clin Cancer Res; 2003 Jun; 9(6):2049-55. PubMed ID: 12796367
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
Jodrell DI; Bowman A; Rye R; Byrne B; Boddy A; Rafi I; Taylor GA; Johnston A; Clendeninn NJ
Br J Cancer; 1999 Feb; 79(5-6):915-20. PubMed ID: 10070890
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate.
McDonald AC; Vasey PA; Adams L; Walling J; Woodworth JR; Abrahams T; McCarthy S; Bailey NP; Siddiqui N; Lind MJ; Calvert AH; Twelves CJ; Cassidy J; Kaye SB
Clin Cancer Res; 1998 Mar; 4(3):605-10. PubMed ID: 9533527
[TBL] [Abstract][Full Text] [Related]
20. A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.
Hao D; Hammond LA; Eckhardt SG; Patnaik A; Takimoto CH; Schwartz GH; Goetz AD; Tolcher AW; McCreery HA; Mamun K; Williams JI; Holroyd KJ; Rowinsky EK
Clin Cancer Res; 2003 Jul; 9(7):2465-71. PubMed ID: 12855619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
